CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin

HOUSTON, June 11, 2020 -- (Healthcare Sales & Marketing Network) -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and me... Biopharmaceuticals, Oncology, Neurology, FDA CNS Pharmaceuticals, Berubicin, glioma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news